Sienna Biopharmaceuticals, Inc. (SNNA) financial statements (2020 and earlier)

Company profile

Business Address 30699 RUSSELL RANCH ROAD, SUITE 140
WESTLAKE VILLAGE, CA 91362
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 4974
Cash and cash equivalents 4974
Restricted cash and investments 00
Other undisclosed current assets 23
Total current assets: 5077
Noncurrent Assets
Property, plant and equipment 00
Intangible assets, net (including goodwill) 1111
Goodwill 1111
Other undisclosed noncurrent assets 4648
Total noncurrent assets: 5760
TOTAL ASSETS: 107137
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 118
Accounts payable 32
Accrued liabilities 53
Employee-related liabilities 33
Business combination, contingent consideration, liability 14 
Other undisclosed current liabilities 00
Total current liabilities: 248
Noncurrent Liabilities
Long-term debt and lease obligation 30 
Long-term debt, excluding current maturities 30 
Liabilities, other than long-term debt 2634
Deferred tax liabilities, net1111
Business combination, contingent consideration, liability 1623
Other undisclosed noncurrent liabilities 04
Total noncurrent liabilities: 5637
Total liabilities: 8146
Stockholders' equity
Stockholders' equity attributable to parent 2791
Common stock  0
Additional paid in capital 183172
Accumulated other comprehensive income 35
Accumulated deficit (159)(86)
Total stockholders' equity: 2791
TOTAL LIABILITIES AND EQUITY: 107137

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Operating expenses (76)(49)
Operating loss: (76)(49)
Nonoperating income (expense) 3(2)
Loss from continuing operations before income taxes: (73)(51)
Income tax benefit  0
Net loss available to common stockholders, diluted: (73)(51)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss: (73)(51)
Other comprehensive loss (2) 
Comprehensive loss: (76)(51)
Other undisclosed comprehensive income, net of tax, attributable to parent  6
Comprehensive loss, net of tax, attributable to parent: (76)(45)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: